Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Heska was a leading provider of advanced diagnostic solutions—especially immunodiagnostics/allergy testing—and imaging equipment to the global veterinary market with a focus on companion animal health. Its flagship technologies include the ALLERCEPT serum IgE allergy tests based on Fc-epsilon receptor technology and innovative digital cytopathology platforms like HeskaView Telecytology. The company also offered routine chemistry panels, hematological analyzers (“Element Series”), infectious disease rapid tests, oncology screening (“Nu.Q” canine cancer blood test), imaging systems (X-ray/digital radiography), ultrasound devices, telemedicine services powered by AI interpretation tools—all aimed at empowering veterinarians to deliver high-quality care efficiently.
In June 2023 it was acquired by Mars Inc.’s Antech division—one of the world’s largest networks of reference labs/pet healthcare providers—integrating its product lines into an even broader suite serving clinics globally through both direct sales/service models and laboratory partnerships across North America & Europe[1][3].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Heska.